- Home
- ONEG vs MURA Comparison
ONEG vs MURA Comparison
Compare ONEG & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONEG
- MURA
- Stock Information
- Founded
- ONEG 2021
- MURA 2013
- Country
- ONEG Hong Kong
- MURA Ireland
- Employees
- ONEG N/A
- MURA N/A
- Industry
- ONEG Homebuilding
- MURA
- Sector
- ONEG Consumer Discretionary
- MURA
- Exchange
- ONEG Nasdaq
- MURA Nasdaq
- Market Cap
- ONEG 43.3M
- MURA 45.8M
- IPO Year
- ONEG 2024
- MURA N/A
- Fundamental
- Price
- ONEG $5.02
- MURA $2.46
- Analyst Decision
- ONEG
- MURA Strong Buy
- Analyst Count
- ONEG 0
- MURA 4
- Target Price
- ONEG N/A
- MURA $13.00
- AVG Volume (30 Days)
- ONEG 25.4K
- MURA 106.6K
- Earning Date
- ONEG 01-01-0001
- MURA 08-12-2025
- Dividend Yield
- ONEG N/A
- MURA N/A
- EPS Growth
- ONEG N/A
- MURA N/A
- EPS
- ONEG 0.12
- MURA N/A
- Revenue
- ONEG $60,903,000.00
- MURA N/A
- Revenue This Year
- ONEG N/A
- MURA N/A
- Revenue Next Year
- ONEG N/A
- MURA N/A
- P/E Ratio
- ONEG $40.06
- MURA N/A
- Revenue Growth
- ONEG 16.46
- MURA N/A
- 52 Week Low
- ONEG $1.48
- MURA $0.95
- 52 Week High
- ONEG $5.78
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- ONEG N/A
- MURA 44.84
- Support Level
- ONEG N/A
- MURA $2.51
- Resistance Level
- ONEG N/A
- MURA $2.66
- Average True Range (ATR)
- ONEG 0.00
- MURA 0.09
- MACD
- ONEG 0.00
- MURA -0.02
- Stochastic Oscillator
- ONEG 0.00
- MURA 20.08
About ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. It is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project include performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.